Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis: Case report and literature review
Introduction. Ocrelizumab is a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, which is approved for the treatment of the relapsing and primary progressive multiple sclerosis (MS). It is extremely rarely associated with late-onset neutropenia (LON), as an...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Serbian Medical Society
2022-01-01
|
| Серии: | Srpski Arhiv za Celokupno Lekarstvo |
| Предметы: | |
| Online-ссылка: | http://www.doiserbia.nb.rs/img/doi/0370-8179/2022/0370-81792200042J.pdf |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|